Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 158   

Articles published

NVS 80.11 -0.03 (-0.04%)
price chart
Novartis AG (ADR) Plunges on Profit Miss
Novartis AG (ADR) (NYSE:NVS) reported lower-than-expected fourth quarter and full year earnings data for fiscal 2015 today, driven mostly by its struggling eye-care business and strengthened dollar.
Novartis and the 'T' Word  Bloomberg
Novartis (NVS) Posts Lower-Than-Expected Earnings in Q4  Nasdaq
Novartis Continues Efforts To Gain Larger Market For Entresto
Novartis AG (ADR) (NYSE:NVS) is working diligently to bring back heart failure drug Entresto, after the drug's not-so-impressive introduction in the market.
Novartis Announces The Establishment Of FortiHFy, But What Is It?  Benzinga
Novartis AG (ADR) Under Pressure on Q1 Revenue Decline
Novartis AG (ADR) (NYSE:NVS) has reported financial results for the first quarter of fiscal year 2016 (1QFY16) with a decline in both, its earnings and revenues.
Novartis (NVS) Misses On Earnings & Sales in Q1  Nasdaq
Novartis (NVS) Q1 Earnings Miss; Gleevec Hit by Generics  Yahoo News
Here's Why Novartis AG (ADR) Fared Better Than Others
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA  CNA Finance (press release)
Bimagrumab (BYM338) drug from Novartis AG (ADR) (NYSE:NVS) Failed a Phase IIb ...
Bimagrumab (BYM338) from Novartis AG (ADR) (NYSE:NVS) failed a Phase IIb/III study. The news of the failure of the study pertaining to a rare, muscle-wasting disease known as sporadic inclusion body myositis was heartbreaking for the pharma giant since ...
Amgen, Inc. (NASDAQ:AMGN) Has Sued Novartis' AG (ADR) (NYSE:NVS) Sandoz Unit ...
Top-selling anti-inflammatory drug Enbrel from Amgen, Inc. (NASDAQ:AMGN) is facing steep competition from biosimilars that are hitting the market at a very rapid speed.
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) Entresto Clinches EU approval
Novartis Pharmaceuticals UK's Chief Scientific Officer, Dimitrios Georgiopoulos, says, “Heart failure is a life-threatening condition that leaves a major impact on patients and their carers.
Novartis Gets EU Approval for Cardiovascular Drug Entresto
Will Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) And Novartis AG (ADR ...
It is not clear whether Teva's Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Novartis AG (ADR)(NYSE:NVS) are trying to fend off copy cats.